← Human Trials & Peer-Reviewed Studies
Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.
Plain-language guide to PMID 12612296 (2003): double-blind randomized controlled trial of Vasoactive Intestinal Peptide.
Key Facts
- PMID
- 12612296
- Journal
- Thorax
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- Lindén A et al. (8 authors)
- DOI
- 10.1136/thorax.58.3.217
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vasoactive Intestinal Peptide, published as a randomized controlled trial.
The synthetic vasoactive intestinal peptide (VIP) analogue Ro 25-1553 is a selective VIP-PACAP type 2 (VPAC(2)) receptor agonist that causes a bronchodilatory effect in guinea pigs in vivo.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, men only.
Twenty four patients with moderate stable asthma participated in a double blind, randomised, placebo controlled, crossover study.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
The participants were allocated by chance, so the Vasoactive Intestinal Peptide group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Vasoactive Intestinal Peptide.
A placebo (an inactive look-alike) gave the Vasoactive Intestinal Peptide group a baseline to be compared against.
Each person switched between Vasoactive Intestinal Peptide and the comparison at some point, usually with a gap in between.
Putative side effects were characterised by monitoring sitting blood pressure, serum potassium, electrocardiography and echocardiography.
What Was Measured
The synthetic vasoactive intestinal peptide (VIP) analogue Ro 25-1553 is a selective VIP-PACAP type 2 (VPAC(2)) receptor agonist that causes a bronchodilatory effect in guinea pigs in vivo.
Topics PubMed links to this paper include Administration, Inhalation, Anti-Asthmatic Agents, Asthma, Bronchodilator Agents, Forced Expiratory Volume, Peptides, Cyclic and Vasoactive Intestinal Peptide.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vasoactive Intestinal Peptide.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2003 (Thorax), a journal based in England.
More context: the related VIP (Vasoactive Intestinal Peptide) library page, all human trials.
Related Library Page
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.